Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 86, Issue 3, 2014, Pages 361-368

  Angi, Réka ^a   Solymosi, Tamás ^a   Ötvös, Zsolt ^a   Ordasi, Betti ^a   Glavinas, Hristos ^a   Filipcsei, Genovéva ^a   Heltovics, Gábor ^a   Darvas, Ferenc ^a  

^a NANGENEX INC   (Hungary)

Author keywords

Aprepitant; Bioavailability; Continuous flow nanoprecipitation; Food effect; In vitro in vivo correlation; Solubility

Indexed keywords

APREPITANT; NANOMATERIAL; STABILIZING AGENT; MORPHOLINE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS FLOW PRECIPITATION; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG ELIMINATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FLOW RATE; FOOD; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHARMACOKINETICS; PHYSICOCHEMICAL MODEL; SOLID; TECHNOLOGY; TEMPERATURE; ANIMAL; CHEMISTRY; CROSSOVER PROCEDURE; DOG; MEDICINAL CHEMISTRY; PROCEDURES; RANDOMIZATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOGS; MORPHOLINES; NANOSTRUCTURES; PARTICLE SIZE; RANDOM ALLOCATION;

EID: 84898475904     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.10.004     Document Type: Article

References (29)

1. T.R. Shaw, and J.E. Carless The effect of particle size on the absorption of digoxin European Journal of Clinical Pharmacology 7 1974 269 273
2. D.M. Oh, R.L. Curl, and G.L. Amidon Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model Pharmaceutical Research 10 1993 264 270
3. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharmaceutical Research 12 1995 413 420
4. R.H. Muller, and K. Peters Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique International Journal of Pharmaceutics 160 1998 229 237
5. N. Rawat, M.S. Kumar, and N. Mahadevan Solubility: particle size reduction is a promising approach to improve the bioavailability of lipophillic drugs International Journal of Recent Advances in Pharmaceutical Research 1 2011 8 18
6. S. Katteboinaa, G. Dist, and A. Pradesh Drug nanocrystals: a novel formulation approach for poorly soluble drugs International Journal of PharmTech Research 1 2009 682 694
7. M. Bindu, B. Kusum, and D. Banji Novel strategies for poorly water soluble drugs International Journal of Pharmaceutical Sciences Review and Research 4 2010 76 84
8. B. Jiang, L. Hu, C. Gao, and J. Shen Ibuprofen-loaded nanoparticles prepared by a co-precipitation method and their release properties International Journal of Pharmaceutics 304 2005 220 230
9. H. Kim do, M.D. Kim, C.W. Choi, C.W. Chung, S.H. Ha, C.H. Kim, Y.H. Shim, Y.I. Jeong, and D.H. Kang Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer Nanoscale Research Letters 7 2012 91
10. H. Chen, C. Khemtong, X. Yang, X. Chang, and J. Gao Nanonization strategies for poorly water-soluble drugs Drug Discovery Today 16 2011 354 360
11. V. Kumar, L. Wang, M. Riebe, H.H. Tung, and R.K. Prud'homme Formulation and stability of itraconazole and odanacatib nanoparticles: governing physical parameters Molecular Pharmaceutics 6 2009 1118 1124
12. W. Yang, J. Tam, D.A. Miller, J. Zhou, J.T. McConville, K.P. Johnston, and R.O. Williams 3rd High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers International Journal of Pharmaceutics 361 2008 177 188
13. H. De Waard, W.L.J. Hinrichs, and H.W. Frijlink A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying Journal of Controlled Release 128 2008 179 183
14. C.L. Ventola The nanomedicine revolution: Part 2: current and future clinical applications Pharmacy and Therapeutics 37 2012 582 591
15. D. Campos, J.R. Pereira, R.R. Reinhardt, C. Carracedo, S. Poli, C. Vogel, J. Martinez-Cedillo, A. Erazo, J. Wittreich, L.O. Eriksson, A.D. Carides, and B.J. Gertz Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone Journal of Clinical Oncology 19 2001 1759 1767
16. Y. Wu, A. Loper, E. Landis, L. Hettrick, L. Novak, K. Lynn, C. Chen, K. Thompson, R. Higgins, U. Batra, S. Shelukar, G. Kwei, and D. Storey The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human International Journal of Pharmaceutics 285 2004 135 146
17. R.I. Sanchez, R.W. Wang, D.J. Newton, R. Bakhtiar, P. Lu, S.H. Chiu, D.C. Evans, and S.E. Huskey Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant Drug Metabolism and Disposition: The Biological Fate of Chemicals 32 2004 1287 1292
18. C.R. Shadle, Y. Lee, A.K. Majumdar, K.J. Petty, C. Gargano, T.E. Bradstreet, J.K. Evans, and R.A. Blum Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity Journal of Clinical Pharmacology 44 2004 215 223
19. R. Takano, K. Furumoto, K. Shiraki, N. Takata, Y. Hayashi, Y. Aso, and S. Yamashita Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation Pharmaceutical Research 25 2008 2334 2344
20. N. Parrott, V. Lukacova, G. Fraczkiewicz, and M.B. Bolger Predicting pharmacokinetics of drugs using physiologically based modeling - application to food effects The AAPS Journal 11 2009 45 53
21. R. Takano, N. Takata, K. Shiraki, S. Higo, Y. Hayashi, and S. Yamashita A theoretical-empirical analysis on the initial dissolution rate of drugs from polydispersed particles Biological & Pharmaceutical Bulletin 32 2009 1885 1891
22. Y. Shono, E. Jantratid, F. Kesisoglou, C. Reppas, and J.B. Dressman Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans European Journal of Pharmaceutics and Biopharmaceutics 76 2010 95 104
23. A.K. Majumdar, L. Howard, M.R. Goldberg, L. Hickey, M. Constanzer, P.L. Rothenberg, T.M. Crumley, D. Panebianco, T.E. Bradstreet, A.J. Bergman, S.A. Waldman, H.E. Greenberg, K. Butler, A. Knops, I. De Lepeleire, N. Michiels, and K.J. Petty Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers Journal of Clinical Pharmacology 46 2006 291 300
24. J.B. Dressman, and C. Reppas In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs European Journal of Pharmaceutical Sciences 11 Suppl. 2 2000 S73 S80
25. K.A. Youdim, A. Avdeef, and N.J. Abbott In vitro trans-monolayer permeability calculations: often forgotten assumptions Drug Discovery Today 8 2003 997 1003
26. M. Kansy, F. Senner, and K. Gubernator Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes Journal of Medicinal Chemistry 41 1998 1007 1010
27. S. Bendels, O. Tsinman, B. Wagner, D. Lipp, I. Parrilla, M. Kansy, and A. Avdeef PAMPA - excipient classification gradient map Pharmaceutical Research 23 2006 2525 2535
28. Katteboina Suman, Rama Krishna Raparla, and Talasila Eswara Gopala Krishna Murthy Formulation and optimization of directly compressible ambroxol HCl controlled release matrix tablets Research Journal of Pharmacy and Technology 3 1 2010 263 266
29. Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them, WO/2011/158053.